LeadStory

10 News First

Novo Nordisk makes another push to add Wegovy to PBS

10 News First · Just In
10 News First
10 News First
Just In

Novo Nordisk has submitted a third application to have its weight-loss drug Wegovy subsidised under Australia's Pharmaceutical Benefits Scheme, this time targeting overweight or obese patients with cardiovascular disease.

Breakdown
  • Novo Nordisk has submitted a third application to list Wegovy on the PBS.
  • Previous applications were rejected due to concerns about the cost to the health system. 13s
  • The latest submission targets overweight or obese patients with cardiovascular disease. 28s
  • Wegovy currently costs between $345 and $645 per month. 35s
  • The Pharmaceutical Benefits Advisory Committee will consider the submission in early November. 41s
Companies & StartupsHealth